Skip to Content

  • Search

View Additional Section Content

A Phase 3B Study to Evaluate the Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients with Stable Cardiovascular Disease and Glucose Abnormalities

Principal Investigator(s)
Michael Seidner, M.D.

Clinical Trial Categories

  • Cardiac Risk Reduction
Contact
Renee Backer, CCRC at 215-361-7164
or research@greenandseidner.com

Location

  • Green and Seidner Family Practice Associates, PC
    826 North Broad Street
    Lansdale, PA 19446
    Office: 215-855-1054
    Fax: 215-855-3786

Find a Physician
Search Our Directory

215-481-MEDI

Schedule a Test
Request an Appointment

215-481-EXAM

Clinical Trials Details